Ark Investment Management CEO Cathie Wood recently purchased an additional $2.8 million in Beam Therapeutics shares. The gene-editing biotech stock has fallen over 14% this year, yet Wood maintains a $220 million position.
Cathie Wood, CEO and founder of Ark Investment Management, has continued to accumulate shares in Beam Therapeutics (NASDAQ: BEAM) despite significant year-to-date losses for the stock. According to recent filings and market data, Wood owns approximately $220.4 million in Beam shares through her various Ark exchange-traded funds. The gene-editing biotech company has seen its share price decline by more than 14% in 2026, with the stock trading at $23.47 as of the close on October 16, 2026.
Wood’s commitment to the position was reinforced in mid-October. On October 12 and October 13, she directed an additional $2.8 million into Beam shares specifically for the Ark Genomic Revolution ETF (NYSEMKT: ARKG). This move follows a holding period of more than five years, during which Wood has maintained exposure to Beam through her technology-focused funds. The recent purchases suggest continued confidence in the company’s long-term trajectory, even as short-term volatility persists.
Beam Therapeutics focuses on developing precision medicines using gene-editing technology. Unlike first-generation CRISPR-Cas9 systems, which create double-stranded DNA breaks and carry risks of unintended chromosomal rearrangements, Beam specializes in base editing. This approach allows for precise, single-letter chemical edits to the genome without cutting both strands of DNA. By targeting specific nucleotides, the technology aims to enable safer and more repeatable therapeutic interventions, positioning the company at the forefront of next-generation genomic medicine.
Despite its technological differentiation, Beam remains a pre-profitability company. All of its current revenue is derived from collaborations rather than product sales, and it maintains a deep pipeline of early-stage gene-editing therapies. Investors considering the stock must weigh these long-term potential benefits against the inherent risks of biotech volatility and the company’s distance from commercial profitability. Wood’s recent buying activity highlights a strategy of accumulating assets during periods of market weakness, a tactic that requires patience and a high tolerance for risk.